Indaptus Therapeutics (INDP) Stock Price, News & Analysis

Company Overview

Indaptus Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors. The company is also exploring applications in antiviral immunotherapies, reflecting the versatility of its platform. By combining advanced engineering techniques with scalable manufacturing processes, Indaptus aims to deliver off-the-shelf therapies to patients with unmet medical needs.

Headquartered in the United States, Indaptus collaborates with academic institutions and contract research organizations to advance discovery and clinical translation. Since its inception, the company has established state-of-the-art research and development facilities to support process development, preclinical evaluation, and future clinical manufacturing. Led by a management team with deep experience in cell and gene therapy development, Indaptus is positioned to move its lead programs into early-phase clinical trials and expand its strategic partnerships in the biopharmaceutical industry.

Key Stats

• Today's Range: $3.02 to $3.35
• 50-Day Range: $2.28 to $9.51
• 52-Week Range: $2.22 to $58.24
• Volume: 106,918 shs
• Average Volume: 1.19 million shs
• Market Capitalization: $3.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $238.00
• Consensus Rating: Hold

Indaptus Therapeutics Stock Analysis - MarketRank™

Indaptus Therapeutics scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Indaptus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Indaptus Therapeutics has a consensus price target of $238.00, representing about 7,360.8% upside from its current price of $3.19.

Amount of Analyst Coverage

Indaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indaptus Therapeutics is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indaptus Therapeutics is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Indaptus Therapeutics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

54.73% of the float of Indaptus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Indaptus Therapeutics has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Indaptus Therapeutics has recently increased by 3,524.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indaptus Therapeutics does not currently pay a dividend.

Dividend Growth

Indaptus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

54.73% of the float of Indaptus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Indaptus Therapeutics has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Indaptus Therapeutics has recently increased by 3,524.50%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Indaptus Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Indaptus Therapeutics this week, compared to 1 article on an average week.

Search Interest

5 people have searched for INDP on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.80% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.06% of the stock of Indaptus Therapeutics is held by institutions.

INDP Stock Analysis - Frequently Asked Questions

How have INDP shares performed this year?

Indaptus Therapeutics' stock was trading at $23.5788 at the beginning of the year. Since then, INDP stock has decreased by 86.5% and is now trading at $3.19.

How were Indaptus Therapeutics' earnings last quarter?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($9.09) EPS for the quarter, missing the consensus estimate of ($0.36) by $8.73.

When did Indaptus Therapeutics' stock split?

Shares of Indaptus Therapeutics reverse split on Friday, June 27th 2025.A 1-28 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Indaptus Therapeutics?

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Indaptus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), GE Aerospace (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INDP
• CIK: 1857044
• Web: intecpharma.com
• Phone: (646) 427-2727
• Fax: 972-2586-9176
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Indaptus Therapeutics: $238.00
• High Price Target: $336.00
• Low Price Target: $140.00
• Potential Upside/Downside: +7,360.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($37.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.02 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -612.59%
• Return on Assets: -243.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.75
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.84 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 1,107,000
• Free Float: 877,000
• Market Cap: $3.53 million
• Optionable: Not Optionable
• Beta: 1.13